Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

2.3%

1 terminated/withdrawn out of 44 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

11%

5 trials in Phase 3/4

Results Transparency

0 of 13 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

16(40.0%)

Phase 1

10(25.0%)

N/A

8(20.0%)

Phase 4

3(7.5%)

Phase 3

2(5.0%)

Early Phase 1

1(2.5%)

40Total

Phase 2(16)

Phase 1(10)

N/A(8)

Phase 4(3)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials

NCT07304258Phase 2Not Yet Recruiting

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Role: lead

NCT07008313Not ApplicableCompleted

Enhanced Recovery After Surgery Promotes the Rehabilitation of Patients With Acute Gastrointestinal Perforation in Perioperative Period

Role: lead

NCT06960486Not ApplicableCompleted

Ultrasound-guided Biliary Drainage Improving Prognosis in the Frail and High Risk Elderly Patients

Role: lead

NCT06934824Not ApplicableNot Yet Recruiting

Clinical Study of Double-Endoscopic Combined With Minimally Invasive Treatment for Early Gastric Cancer at Clinical Stage T1b

Role: lead

NCT06534814Recruiting

Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

Role: lead

NCT06201585Not ApplicableUnknown

Exploratory Study of Single-port Robot-assisted Gastrectomy

Role: lead

NCT06172556Completed

Early Brain Damage Assessment in Aneurysmal Subarachnoid Haemorrhage in Predicting Cognitive Impairment

Role: lead

NCT05229874Phase 2Unknown

Effect of CNSI vs. ICG in Lymph Node Tracing During Gastrectomy

Role: lead

NCT06073483Not ApplicableUnknown

Exploratory Study of Toumai Endoscopic Surgery System for Remote Gastrectomy

Role: lead

NCT05741099Phase 1Unknown

Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection

Role: lead

NCT05728606Not ApplicableUnknown

Robot-assisted D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers

Role: lead

NCT05410847Phase 2Unknown

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Role: lead

NCT05385185Phase 2Unknown

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

Role: lead

NCT01962246Phase 2Completed

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction

Role: lead

NCT03451734Completed

Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients

Role: collaborator

NCT04482868Not ApplicableCompleted

Percutaneous Screw Fixation for Acute Scaphoid Fractures Through K-wire-assisted Reduction and Maintenance

Role: lead

NCT03986385Phase 3Unknown

Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Role: lead

NCT03368131Phase 2Unknown

Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study

Role: lead

NCT03349866Phase 2Unknown

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Role: lead

NCT01516944Phase 2Completed

Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

Role: lead